Kuros Biosciences Ag Stock Net Income
| CSBTF Stock | USD 31.91 0.00 0.00% |
As of the 10th of February, Kuros Biosciences secures the Mean Deviation of 0.5595, risk adjusted performance of (0.08), and Standard Deviation of 1.69. Kuros Biosciences AG technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kuros Biosciences risk adjusted performance, standard deviation, as well as the relationship between the Standard Deviation and maximum drawdown to decide if Kuros Biosciences AG is priced some-what accurately, providing market reflects its recent price of 31.91 per share. Given that Kuros Biosciences has variance of 2.87, we recommend you to check Kuros Biosciences's last-minute market performance to make sure the company can sustain itself at a future point.
Kuros Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kuros Biosciences' valuation are provided below:Kuros Biosciences AG does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Kuros |
Kuros Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kuros Biosciences' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kuros Biosciences.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Kuros Biosciences on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Kuros Biosciences AG or generate 0.0% return on investment in Kuros Biosciences over 90 days. Kuros Biosciences is related to or competes with CStone Pharmaceuticals, SanBio Company, Pharma Mar, PeptiDream, Ascletis Pharma, Pharming Group, and Neuren Pharmaceuticals. Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical... More
Kuros Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kuros Biosciences' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kuros Biosciences AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 14.87 |
Kuros Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kuros Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kuros Biosciences' standard deviation. In reality, there are many statistical measures that can use Kuros Biosciences historical prices to predict the future Kuros Biosciences' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | 1.5 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kuros Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kuros Biosciences February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 1.51 | |||
| Mean Deviation | 0.5595 | |||
| Coefficient Of Variation | (950.75) | |||
| Standard Deviation | 1.69 | |||
| Variance | 2.87 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | 1.5 | |||
| Maximum Drawdown | 14.87 | |||
| Skewness | (3.71) | |||
| Kurtosis | 22.27 |
Kuros Biosciences Backtested Returns
Kuros Biosciences has Sharpe Ratio of -0.11, which conveys that the firm had a -0.11 % return per unit of risk over the last 3 months. Kuros Biosciences exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kuros Biosciences' Standard Deviation of 1.69, mean deviation of 0.5595, and Risk Adjusted Performance of (0.08) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.13, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Kuros Biosciences are expected to decrease at a much lower rate. During the bear market, Kuros Biosciences is likely to outperform the market. At this point, Kuros Biosciences has a negative expected return of -0.19%. Please make sure to verify Kuros Biosciences' information ratio and kurtosis , to decide if Kuros Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.77 |
Almost perfect reverse predictability
Kuros Biosciences AG has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Kuros Biosciences time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kuros Biosciences price movement. The serial correlation of -0.77 indicates that around 77.0% of current Kuros Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.77 | |
| Spearman Rank Test | -0.76 | |
| Residual Average | 0.0 | |
| Price Variance | 7.57 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Kuros Biosciences AG reported net income of (7.54 Million). This is 102.21% lower than that of the Healthcare sector and 110.77% lower than that of the Biotechnology industry. The net income for all United States stocks is 101.32% higher than that of the company.
Kuros Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kuros Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kuros Biosciences could also be used in its relative valuation, which is a method of valuing Kuros Biosciences by comparing valuation metrics of similar companies.Kuros Biosciences is currently under evaluation in net income category among its peers.
Kuros Fundamentals
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 40.53 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 35.33 % | |||
| Shares Owned By Institutions | 16.83 % | |||
| Price To Earning | 0.33 X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.63 X | |||
| Revenue | 13.81 M | |||
| Gross Profit | 10.07 M | |||
| EBITDA | (5.29 M) | |||
| Net Income | (7.54 M) | |||
| Cash And Equivalents | 28.62 M | |||
| Cash Per Share | 0.87 X | |||
| Total Debt | 2.21 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 2.23 X | |||
| Cash Flow From Operations | (5.45 M) | |||
| Earnings Per Share | (0.24) X | |||
| Number Of Employees | 64 | |||
| Beta | 0.77 | |||
| Market Capitalization | 70.16 M | |||
| Total Asset | 91.34 M | |||
| Retained Earnings | (37 M) | |||
| Working Capital | 16 M | |||
| Current Asset | 18 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 18.6 | |||
| Net Asset | 91.34 M |
About Kuros Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kuros Biosciences AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kuros Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kuros Biosciences AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Kuros Pink Sheet
Kuros Biosciences financial ratios help investors to determine whether Kuros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kuros with respect to the benefits of owning Kuros Biosciences security.